Monday, November 17, 2014

The following bids, mergers, acquisitions and disposals were reported by 1430 GMT on Monday:** Allergan Inc agreed to be bought by Actavis Plc for $66 billion, more than $12 billion above the current value of a hostile bid by activist investor William Ackman and Valeant Pharmaceuticals International Inc.

Shares of ACT traded higher by 3.82% or $9.315/share to $253.08. In the past year, the shares have traded as low as $156.40 and as high as $254.41. On average, 2179940 shares of ACT exchange hands on a given day and today's volume is recorded at 6340063.

Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. Shares of AGN traded higher by 7.36% or $14.619/share to $213.27. In the past year, the shares have traded as low as $94.98 and as high as $200.99. On average, 2296180 shares of AGN exchange hands on a given day and today's volume is recorded at 6860094.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 0.67% or $0.9/share to $135.11. In the past year, the shares have traded as low as $105.17 and as high as $153.10. On average, 2526030 shares of VRX exchange hands on a given day and today's volume is recorded at 3009598.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 0.97% or $1.47/share to $152.94. In the past year, the shares have traded as low as $110.26 and as high as $170.45. On average, 468460 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 138763.

Please Donate

Article Archive

The reports on this site are for information purposes only and are not a recommendation for the purchase of securities. The information contained in these reports have been gathered from sources we believe to be reliable, however, we make no guarantee as to the accuracy or completeness to such information.